5ST-16839-02557 · OpenVSafe

Timeline

Registration Vaccinations Survey responses Call reports Cases without a report Call attempts Call successful Pregnancy survey

2023-01-12
Dose 1 — Pfizer-BioNTech
Co-administered: Hepatitis A:Hib:Tetanus
2023-01-13
Registered in v-safe
2023-01-13
Health check-in — days 1–6 daily, dose 1, under 3
Feeling: Good · Irritability/crying

Under 3 check-in
2023-01-14
Health check-in — days 1–6 daily, dose 1, under 3
Feeling: Good · None

Under 3 check-in
2023-01-16
Health check-in — days 1–6 daily, dose 1, under 3
Feeling: Good · None

Under 3 check-in
2023-01-17
Health check-in — days 1–6 daily, dose 1, under 3
Feeling: Good · None

Under 3 check-in
2023-01-26
Health check-in — day 14, dose 1, under 3
Feeling: Good

Under 3 check-in
2023-02-02
Survey response — day 21, dose 1, under 3
MedDRA: Herpangina, Lacrimation increased, Nasal congestion, Pyrexia — Feeling: Poor · Be unable to work or attend school

MedDRA releases: 2024-11

Vaccinations

Dose	Date	Manufacturer	Co-administered
1	2023-01-12	Pfizer-BioNTech	Hepatitis A:Hib:Tetanus

Free text

None.

Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".

MedDRA terms by release

Field	Preferred term	2021-09	2023-04	2024-11
SD	Herpangina	·	·	✓
SD	Lacrimation increased	·	·	✓
SD	Nasal congestion	·	·	✓
SD	Pyrexia	·	·	✓

✓ active code · ○ coded but marked inactive · blank = not in that release